This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic / pharmacodynamic characteristics. Adverse events, physical examinations, vital signs, ECG and laboratory tests will be conducted for safety/tolerability evaluation and serial blood samples and urine collections for pharmacokinetic and pharmacodynamic evaluations will be conducted at specified time points.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
129
Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
Seoul National University Hospital
Seoul, South Korea
Adverse events of LC350189
Time frame: 7 days(plus or minus 1 day)
Cmax
Time frame: 3 days
AUC
Time frame: 3days
Tmax
Time frame: 3days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.